KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients
The drug did, however, significantly improve progression-free survival.
Diagnosis & Disease Information
Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated
Encouraging activity noted in several tumor types.
Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
Tyrer-Cuzick Breast Cancer Model Well-Calibrated Among Most Races/Ethnicities
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
- Loading...
Loading...
Next post in ASCO 2020 HCC In-Depth
Loading... 
Loading...